Published Date: 17-Mar-2020
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report Global Tumor Ablation Market, published by KBV Research, The Global Tumor Ablation Market size is expected to reach $1.7 billion by 2025, rising at a market growth of 10.9% CAGR during the forecast period.
The surgical ablation segment sustained a significant share in 2019, increased pervasiveness of liver and breast cancer, and inaccessibility of advanced tumor ablation techniques for these particular organs are the key factors expected to boost the segment growth. The percutaneous ablation segment is expected to show lucrative growth during the forecast period. These procedures provide faster recovery, minimal scarring, and improved safety.
Liver cancer dominated the market share in 2018. This can be associated with the growing prevalence of bile duct cancer and primary liver cancer. The segment of the lung cancer application is expected to grow at 12% CAGR over the forecast period. This can be due to the growing epidemic of the disease. The Breast Cancer market is poised to grow at a CAGR of 10.1% during (2019 - 2025). Additionally, The Kidney Cancer market is expected to witness highest CAGR of 15.4% during (2019 - 2025).
The North America market dominated the Global Tumor Ablation Market by Region 2018. The Europe market is experiencing a growth rate CAGR of 10% during (2019 - 2025).The Asia Pacific is predicted to have the fastest growth rate throughout the forecast period. Expanding the patient population and increasing the presence of major healthcare providers in rapidly developing economies, like India and China, opens up opportunities for growth.
Structural Insights: https://www.kbvresearch.com/tumor-ablation-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Medtronic PLC, Johnson and Johnson (Ethicon, Inc.), Boston Scientific Corporation, Misonix, Inc., EDAP TMS S.A., Theraclion SA, AngioDynamics, Inc., Mermaid Medical A/S, HealthTronics, Inc. (Altaris Capital Partners, LLC), and SonaCare Medical, LLC.
Unique Offerings from KBV Research